NCT07220083View on ClinicalTrials.gov

A Study to Find Out if BI 764198 Helps Adults and Adolescents With a Kidney Condition Called Focal Segmental Glomerulosclerosis (FSGS)

PHASE3Not yet recruitingINTERVENTIONAL
Enrollment

286

Participants

Timeline

Start Date

December 5, 2025

Primary Completion Date

February 20, 2030

Study Completion Date

March 20, 2030

Conditions
Focal Segmental Glomerulosclerosis
Interventions
DRUG

BI 764198

BI 764198

DRUG

Placebo

Placebo matching BI 764198

Sponsors
All Listed Sponsors
lead

Boehringer Ingelheim

INDUSTRY